The three patents -- 11,060,098, 11,060,109, and 11,060,086 -- are for three additional orthogonal enzymes and expand the scope of the company's Leap-In Transposase platform. The pairs were engineered using Atum's ProteinGPS platform, which enables the rapid generation of stable transposon integrations and the controlled excision of genetic elements.

With the addition of the new genome engineering technology, the company believes it can apply its bioengineering tools to a spectrum of complex, multidimensional bioengineering applications on the genome level.

Atum's transposon- and transposase-based platform addresses some of the limitations of CRISPR-Cas9 editing technology and has direct applications for efficient recombinant protein expression, cell line development, cell and gene therapy, and other genomic engineering applications, according to the company.

Atum licenses cell line development tools to Rentschler Biopharma
Rentschler Biopharma has signed a full contract development and manufacturing organization license agreement for Atum's Leap-In Transposase platform.

Atum, Phylex accelerate universal SARS coronavirus vaccine
Atum and Phylex BioSciences will collaborate to advance research toward creating a universal vaccine effective against pathogenic coronaviruses, including...